Randomized study of single instillation of epirubicin for superficial bladder carcinoma: Long-term clinical outcomes

Cancer Investigation

Volumn 24, Issue 2, 2006, Pages 160-163

  Liu, Benchun ^a,b   Wang, Zhong ^c   Chen, Bo ^a   Yu, Jiang ^a   Zhang, Peng ^a   Ding, Qiang ^a   Zhang, Yuanfang ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Chemotherapeutic agent; Epirubicin; Prophylactic treatment; Superficial bladder carcinoma

Indexed keywords

EPIRUBICIN; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DYSURIA; FOLLOW UP; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; URETHRA STRICTURE; URINARY FREQUENCY; URINARY URGENCY;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; EPIRUBICIN; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33645004051     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500524405     Document Type: Article

References (21)

1. Liu, B.; Zhang, Y. The role of epirubicin in treatment and prevention recurrence of bladder carcinoma. China Oncol. 1998, 8, 232-234.
2. Zhang, Y.; Zhang, Z.; Tang, Y.; et al. Single and consecutive instillation of epirubicin and mitomicin C for prevention recurrence of bladder carcinoma. China Oncol. 2000, 10, 211-214.
3. Liu, B.; Zhang, Y.; Wang, Z.; et al. Single dose instillation of epirubicin for prevention recurrence of bladder carcinoma. Chinese Surg. 2002, 40, 112-115.
4. Hara, I.; Miyake, H.; Takechi, Y.; et al. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder. Int. J. Urol. 2003, 10, 19-24.
5. Mohanty, N.K.; Malhotra, V.; Nayak, R.L.; Arora, R.P. Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up. J. Chemother. 2002, 14, 194-197.
6. Hausladen, D.A.; Wheeler, M.A.; Altieri, D.C.; et al. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survival levels and outcome. J. Urol. 2003, 170, 230-234.
7. Solsona, E.; Iborra, I; Ricós, J.V.; Monrós, L.; Casanova, J.; Dumont, R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J. Urol. 1999, 161, 1120-1123.
8. Okamura, K.; Kinukawa, T.; Tsmura, Y.; et al. A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Naoya University Urological Oncology Group. Eur. Urol. 1998, 33, 285-288.
9. Maekawa, S.; Suzuki, H.; Ohkubo, K.; Okada, T.; Maeda, H.; Ogura, K.; Arai, Y. Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study. Hiyokika kiyo 2000, 46, 301-306.
10. Kondo, T.; Onitsuka, S.; Ryoji, O.; et al. Analysis of prognostic factors related to primary superficial bladder cancer tumor recurence in prophylactic intravesical epirubicin therapy. Int. J. Urol. 1999, 6, 178-183.
11. de Reijke, T.M.; Kurth, K.H.; Sylvester, R.J.; Hall, R.R.; Brausi, M.; et al. European Organization for the Research and Treatment of Cancer-Genito-Urinary Group. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906). J. Urol. 2005, 173 (2), 405-409.
12. Nomata, K.; Noguchi, M.; Kanetake, H.; Tsuda, N.; Hayashi, M.; et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment. Cancer. Chemother. Pharm. 2002, 50 (4), 266-270.
13. Rajala, P.; Kaasinen, E.; Raitanen, M.; Liukkonen, T.; Rintala, E.; Finnbladder Group. Perioperative single dose instillation of epirubicin or interferon-a after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study-Finnbladder III long-term results. J. Urol. 2002, 168, 981-985.
14. Parmar, M.K.B.; Freedman, L.S.; Hargreave, T.B.; Tolley, D.A. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (Urological Cancer Working Party). J. Urol. 1989, 142, 284-288.
15. Lamm, D.L.; Blumenstein, B.A.; Crawford, E.D.; et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette- Guérin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 1991, 325, 1205-1209.
16. Witjes, J.A.; Meijden, A.P.; Sylvester, L.C.; Debruyne, F.M.; van Aubel, A.; et al. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 1998, 52, 403-410.
17. Kurth, K.H.; Bouffioux, C.; Sylvester, R.; van der Meijden, A.P.; Oosterlinck, W.; Brausi, M. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur. Urol. 2000, 37 (Suppl 3), 1-9.
18. Oosterlinck, W.; Kurth, K. H.; Schröder, F.; Bultinck, J.; Hammond, B.; Sylvester, R. Members of the European Organization for Research and Treatment of Cancer Genitourinary Group. A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J. Urol. 1993, 149, 749-752.
19. Tolley, D.A.; Parmar, M.K.B.; Grigor, K.M.; Lallemand, G.; Medical Research Council Superficial Bladder Cancer Working Party. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J. Urol. 1996, 155, 1233-1238.
20. Ali-El-Dein, B.; Nabeeh, A.; El-Baz, M.; Shamaa, S.; Ashamallah, A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: prospective, randomized controlled study. Br. J. Urol. 1997, 79, 731-735.
21. Rajala, P.; Liukkonen, T.; Raitanen, M.; et al. Transurethral resection with perioperative instillation of interferon- or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study-Finnbladder III. J. Urol. 1999, 161, 1133-1136.